By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – MDx Health today announced a deal with Newcastle University in the UK, Cancer Research Technology, and Pfizer to identify and develop biomarkers that can predict response to a PARP inhibitor.
Registering provides access to this and other free content.
Already have an account?Login Now.
In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.
Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.
In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.
Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.